Tobira Development (TBRA) Earns Daily News Impact Rating of 0.16
News stories about Tobira Development (NASDAQ:TBRA) have been trending somewhat positive on Saturday, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Tobira Development earned a news impact score of 0.16 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.8700183224849 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
About Tobira Development
Tobira Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company’s product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5) in late stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure.
Receive News & Stock Ratings for Tobira Development Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Development Inc and related stocks with our FREE daily email newsletter.